What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Donavan T. Cheng, Talia Mitchell, Ahmet Zehir et al. · Journal of Molecular Diagnostics · 2015 · 2.2K citations · Full text

Medicine, Molecular Biology, Oncology +14

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Ryohei Katayama, Alice T. Shaw, Tahsin Khan et al. · Science Translational Medicine · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +17

Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity

Alena Skálová, Tomáš Vaněček, Radek Šíma et al. · The American Journal of Surgical Pathology · 2010 · 1K citations

Medicine, Oncology, Oral Pathology +17

The landscape of kinase fusions in cancer

Nicolas Stransky, Ethan Cerami, Stefanie S. Schalm et al. · Nature Communications · 2014 · 969 citations · Full text

Medicine, Cancer Biology, Oncology +17